CHIASMA
Chiasma applies its proprietary technology to approved drugs, which not only enables their being switched from injectable to oral, but importantly can result in new indications and/or enhanced absorption. The Company's Transient Permeability Enhancer technology promotes the delivery of drugs to the GI wall and from there to the liver. It is applicable to macromolecules that to-date can be administered only by injection. TPE can be utilized also with small molecules that are already orally available but are poorly absorbed.
CHIASMA
Industry:
Biopharma Biotechnology Therapeutics
Founded:
2001-01-01
Address:
Waltham, Massachusetts, United States
Country:
United States
Website Url:
http://www.chiasma.com
Total Employee:
51+
Status:
Active
Contact:
972 2 571 5885
Email Addresses:
[email protected]
Total Funding:
246 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail IPv6 IIS Pound Sterling Microsoft ASP.NET 4.0 Microsoft Azure ASP.NET Ajax
Similar Organizations
Boston Immune Technologies & Therapeutics
This company is a Boston-based biopharmaceutical company developing immune-based approaches.
DiaMedica
DiaMedica is a biopharmaceutical company focused on developing innovative treatments for stroke.
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
Manus Bio
Manus Bio makes nature accessible and affordable for a growing society.
Relypsa
Relypsa is a biopharmaceutical company developing drugs for treating cardiovascular and renal diseases.
Renovis
Renovis,is a biopharmaceutical company developing drugs to treat neurological diseases and disorders.
SAJE Pharma
SAJE Pharma is a bio-pharmaceutical company developing therapeutic agents for respiratory diseases.
SpringWorks Therapeutics
SpringWorks Therapeutics is a biopharmaceutical company that develops medicines for patients with severe rare diseases and cancer.
Thesan Pharmaceuticals
Thesan Pharmaceuticals is a preclinical biopharmaceutical company developing novel therapeutics for skin disorders.
Transition Therapeutics
Transition Therapeutics is a biopharmaceutical company developing novel therapeutics for disease indications with large markets.
Triana Biomedicines
Triana Biomedicines is a developer of a molecular glue discovery platform to regulate disease.
Current Advisors List
Current Employees Featured
Stock Details
Investors List
Poalim Equity
Poalim Equity investment in Post-IPO Equity - Chiasma
Blue Chip Venture Company
Blue Chip Venture Company investment in Series E - Chiasma
Abingworth
Abingworth investment in Series E - Chiasma
Sofinnova Investments
Sofinnova Investments investment in Series E - Chiasma
Rock Springs Capital
Rock Springs Capital investment in Series E - Chiasma
ARCH Venture Partners
ARCH Venture Partners investment in Series E - Chiasma
F2 Ventures
F2 Ventures investment in Series E - Chiasma
MPM Capital
MPM Capital investment in Series E - Chiasma
7 Health Ventures
7 Health Ventures investment in Series E - Chiasma
Abingworth
Abingworth investment in Series D - Chiasma
Official Site Inspections
http://www.chiasma.com Semrush global rank: 7.45 M Semrush visits lastest month: 492
- Host name: 104.21.74.27
- IP address: 104.21.74.27
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Chiasma"
Chiasma, Inc. - AnnualReports.com
Chiasma is focused on developing and commercializing oral therapies to improve the lives of patients who face challenges associated with their existing treatments for rare and serious …See details»
Chiasma Company Profile - Office Locations, Competitors ... - Craft
Aug 9, 2021 Chiasma has 5 employees across 2 locations and $1.11 m in annual revenue in FY 2020. See insights on Chiasma including office locations, competitors, revenue, financials, …See details»
Chiasma Company Profile 2024: Valuation, Investors, Acquisition
Chiasma General Information Description. Developer of oral medications intended to treat rare and debilitating diseases. The company is focused on the commercialization of MYCAPSSA …See details»
Chiasma - Funding, Financials, Valuation & Investors - Crunchbase
Chiasma is registered under the ticker NASDAQ:CHMA . Their stock opened with $16.00 in its Jul 15, 2015 IPO. Stock Symbol NASDAQ:CHMA ; Valuation at IPO $450M; Money Raised at IPO …See details»
Chiasma - Contacts, Employees, Board Members, Advisors & Alumni
Organization. Chiasma . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies ... Chiasma has 4 current employee profiles, including VP …See details»
Chiasma - Org Chart, Teams, Culture & Jobs - The Org
Chiasma is a late-stage biopharmaceutical company focused on improving the lives of patients suffering from orphan diseases by developing and commercializing novel oral forms of …See details»
Chiasma Reports First Quarter Financial Results and Announced …
May 5, 2021 Chiasma is headquartered in Needham, MA with a wholly owned subsidiary in Israel. ... the timing and costs involved in establishing and maintaining a commercial …See details»
Chiasma Overview - Seeking Alpha
Chiasma undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. …See details»
Chiasma - Engage - auckland.campuslabs.com
History: Chiasma was launched in September 2004 by Priv Bradoo, Swati Sharma and Daniel Sun, three PhD students in the University of Auckland’s Faculty of Medical and Health …See details»
Chiasma Announces U.S. Commercial Launch and Availability of …
Aug 31, 2020 Chiasma is headquartered in Needham, MA with a wholly owned subsidiary in Israel. ... the timing and costs involved in establishing a commercial organization, Chiasma’s …See details»
Team - Chiasma
During his PhD, he focused on the way the brain adapts to blindness. Sami finds data fascinating, works as a data scientist and spends a some of his free time finding insights about human …See details»
Chiasma To Merge With Amryt - Nasdaq
May 6, 2021 Commercial-stage biopharmaceutical company Chiasma Inc. (CHMA) announced Q1 results and has also agreed to merge with Amryt Pharma. After jumping 46% on the …See details»
Chiasma Reports First Quarter Financial Results and
May 5, 2021 Information about Chiasma’s directors and executive officers is available in Chiasma’s definitive proxy statement dated April 26, 2021 for its 2021 Annual Meeting of …See details»
Chiasma - Crunchbase Company Profile & Funding
Chiasma is New Zealand's premier student-led non-profit organisation that fosters connections between science and business, connecting university students to high-tech industries. Lists …See details»
Chiasma to Present New Data from Two Phase 3 Trials, CHIASMA …
Mar 10, 2021 Oral Presentation Title: One-Year Outcomes of the Open-Label Extension of CHIASMA OPTIMAL, a Phase 3 Study of Oral Octreotide Capsules in AcromegalyPresenter: …See details»
Chiasma Announces U.S. Commercial Launch and Availability
NEEDHAM, Mass., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to …See details»
Chiasma Announces FDA Approval of MYCAPSSA® (Octreotide) …
Jun 26, 2020 Chiasma, Inc. (CHMA), a commercial stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) approved …See details»
Chiasma to Present New Data from Two Phase 3 Trials, CHIASMA …
Mar 10, 2021 Chiasma is a commercial-stage biopharmaceutical company focused on developing and commercializing oral therapies to improve the lives of patients who face …See details»
CHIASMA Project – Accessible Innovation Methods for SSbD
The CHIASMA Project is fully aligned with the EU strategies for the development of the Safe and Sustainable by Design (SSbD) framework to ensure safety and sustainability of enabling and …See details»